

Innovation all for the patients



Roche A member of the Roche group

## Roche Announces New Five-Year Data of Evrysdi for Type I SMA

TOKYO, June 10, 2024 -- [Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that Roche issued a press release on June 7, regarding five-year data from the FIREFISH study of Evrysdi® (generic name: risdiplam) in type I SMA.

Please refer to the link below for details of the press release:

Five-year data for Roche's Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk

<https://www.roche.com/media/releases/med-cor-2024-06-07>

###